Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Therapure Biopharma to Acquire Plasma Protein Purification Technology

Published: Monday, December 09, 2013
Last Updated: Sunday, December 08, 2013
Bookmark and Share
Therapure and Upfront have entered into an agreement.

Therapure Biopharma Inc. and Upfront Chromatography A/S have announced that they have entered into an agreement for Therapure to acquire the assets and associated business related to human plasma fractionation from Upfront.

Upfront has developed over the last 15 years, a proprietary protein purification technology, based on Expanded Bed Adsorption (EBA) chromatography which offers significant advantages over to other purification technologies.

As a result of the acquisition, Therapure gains exclusive rights for the commercialization of the Upfront technology relevant to the human plasma fractionation field. Therapure will continue to develop and market this technology under the new trademark PlasmaCap EBA.

Nick Green, CEO of Therapure, commented: “The acquisition of the PlasmaCap EBA technology is an important addition to Therapure’s purification portfolio. With PlasmaCap EBA, Therapure now possesses a technology to capture therapeutic plasma proteins that is highly efficient and less damaging to the end product compared to conventional methods of fractionation. Ultimately PlasmaCap EBA allows for a more cost-effective process to manufacture plasma proteins. Therapure has established an excellent reputation as a biologics contract development and manufacturing organization (CDMO) with integrated services including plasma protein purification. The acquisition of this technology will further support Therapure’s reputation as a leader in the biologics manufacturing sector in general, and as a global leader in terms of plasma protein purification. We feel strongly that this technology can add significant value to our clients as they seek to optimize their manufacturing processes and associated economics.”

Upfront divested their pharmaceutical business unit in April 2010 to DSM Biologics, and is now focusing on their BioMine business line, where the technology is offered to the food/feed ingredients business for extraction of food grade proteins.

“We see this additional divestment of our technology to Therapure as a major milestone for Upfront”, commented Michael Pålsson, CEO of Upfront. “It is yet another significant blue-stamp of our technology, driven by its value creation in the capture of high value proteins. We are now ready to focus 100% on our BioMine business which aims to valorize under-utilized side and waste streams from the food, feed and biofuel industries. There is a broad range of food and feed industries in the world with large volumes of side and waste streams containing valuable proteins. We are able to help these manufacturers get more value out of these streams, and at the same time we see a growing, global need for alternative protein sources to feed the world’s population.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Therapure Biopharma Awarded US Government Contract
DoD contract to manufacture materials for anti-nerve gas agent.
Thursday, June 20, 2013
Scientific News
How it Works: Advanced Data Analysis Using Visualization
Visualisation of data can be used to help molecular biologists tackle the vast datasets their experiments create.
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Ebola-Affected Countries Receive NIH Support
The National Institutes of Health has established a new program to further research capacity to study Ebola and other epidemics.
Skin Patch to Treat Peanut Allergy
NIH-funded study suggests peanut protein patch is a safe and convenient method of treatment.
Molecular Origins of Dust Mite Allergy Discovered
Scientists have identified molecules of house dust mites that are targeted by the immune system of children, developing allergic rhinitis and asthma.
Scientists Uncover Why Hepatitis C Vaccine is Difficult to Make
Scientists have uncovered one reason why a successful hepatitis C vaccine continues to be elusive.
Robotic Cleaning Technique Could Automate Neuroscience Research
New robotic cleaning technique allows pipettes used in patch-clamping to be re-used up to 11 or more times.
Startup Seeks More Precise Prostate Cancer Screening
Gregor Diagnostics aims to bring a non-invasive prostate cancer screening test to the market.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos